Marjorie Taylor Greene is a Republican U.S. congresswoman from Georgia known for her outspoken far-right views and loyalty to former President Donald Trump. First elected in 2020, she quickly gained notoriety for promoting controversial conspiracy theories and confronting political opponents.
Greene has positioned herself as a Trump ally and serves on House committees that can influence policy and receive high-level briefings. As a member of Congress, she has access to nonpublic discussions about legislation, national security, and economic policy information that could affect stock prices.
Recently, her stock market activities have drawn as much attention as her politics. Financial disclosures reveal that Greene has actively traded stocks while in office, spurring questions about potential conflicts of interest and even allegations of insider trading.
Critics point to some well-timed trades, occurring right before major world events or policy changes, that gave the appearance of profiting from inside knowledge. We’ll break down the facts behind these trades, the timeline of events, and how the public has responded.
TLDR
- Marjorie Taylor Greene traded stocks while in Congress, raising conflict-of-interest concerns.
- She bought Lockheed Martin days before Russia invaded Ukraine, prompting “war profiteering” claims.
- In 2021, she held vaccine-maker stocks while opposing vaccines, with some trades reported late.
- In April 2025, she bought major tech stocks and sold Treasury bills just before markets rose, triggering insider-trading talk.
- Greene says an adviser manages her portfolio and denies any prior knowledge of events.
- She hasn’t been charged, but late filings keep her trades and broader concerns in the spotlight.
Marjorie Taylor Greene Insider Trading Allegation 1: Lockheed Martin Stock Purchase
One of the first trades that put Greene under fire was her investment in a defense contractor just as war was breaking out in Europe. Below is a timeline of the key events:
February 22, 2022
Greene purchased between $1,000 and $15,000 worth of stock in Lockheed Martin Corp, a major U.S. defense contractor. This buy came only two days before Russian President Vladimir Putin launched a full-scale invasion of Ukraine.
February 24, 2022
Russia invaded Ukraine, an action expected to boost demand for American-made weapons. That same day, Greene tweeted, “War is big business to our leaders,” implying that politicians and companies profit from conflict. Critics immediately pointed out the irony that Greene stood to gain financially from war-related business due to her Lockheed stock.
Early March 2022
House disclosure reports made Greene’s Lockheed stock purchase public, sparking media coverage and condemnation from colleagues. On March 7, 2022, Rep. Ilhan Omar publicly criticized Greene’s trade as a prime example of why lawmakers shouldn’t be trading individual stocks.
Greene’s Response
Facing accusations of “war profiteering,” Greene defended the Lockheed trade through a spokesperson and in a statement to the press. She insisted that an independent financial adviser manages her portfolio and made the Lockheed buy as part of a long-term strategy.
“Our investment advisor has full discretionary authority over our accounts,” Greene noted, adding that Lockheed Martin is an “American company” she’s held for years.
In other words, Greene claimed this was not a quick insider tip but a routine investment decision. She was not found to have violated any laws in this case, but the optics were politically damaging. The incident amplified calls in Congress to ban stock trading by its members.
Marjorie Taylor Greene Insider Trading Allegation 2: Investments in COVID-19 Vaccine Makers
Greene’s stock holdings during the COVID-19 pandemic drew sharp criticism for apparent hypocrisy and raised questions about her disclosures. Key highlights include:
August 2021
Financial disclosure forms revealed that Greene owned shares in three major COVID-19 vaccine manufacturers – Pfizer, Johnson & Johnson, and AstraZeneca. Each holding was valued in the five-figure range (Pfizer and J&J between $15,001 and $50,000 each; AstraZeneca between $1,001 and $15,000).
She reported earning a few hundred dollars in income from each of these stocks. Notably, this disclosure covered 2020 transactions; Greene had acquired some of these stocks while campaigning for office, before she was sworn in.
Public Stance vs. Private Investments
At the same time, Greene was loudly anti-vaccine in her rhetoric. She boasted about being unvaccinated and derided pro-vaccine efforts as tyrannical. In late 2021, this disconnect became a talking point.
Georgia businesswoman Jennifer Strahan, then a primary challenger to Greene, highlighted that Greene “rails against the vaccine, but owns stock in 3 of the 4 major vaccine manufacturers”.
Media and Voter Reactions
The revelation that Greene could profit from vaccines she publicly opposed led to charges of bad faith. Voters and commentators questioned if Greene truly believed the vaccines were harmful, given her financial stake in companies producing them.
The story gained national attention in December 2021. Greene responded by reiterating that she does not personally direct her investments. In other words, Greene implied that any vaccine stock purchases were made by her broker without her specific input.
Disclosure Lapses
Beyond the PR backlash, Greene’s handling of these trades raised legal and ethical flags. Watchdog group End Citizens United filed a complaint in June 2023, accusing Greene of failing to properly disclose dozens of stock transactions in 2020 and 2021.
This complaint specifically noted that Greene “illegally concealed” trades, including her acquiring Pfizer and Johnson & Johnson shares, by not reporting them in the timely manner required under the STOCK Act.
For example, on multiple occasions, stocks appeared on Greene’s annual 2021 report that had not been reported within 45 days of purchase, as the law mandates. One batch of trades made at the end of 2021 wasn’t disclosed until May 2022, well past the deadline.
These filing delays violated congressional rules, though consequences for such violations (typically small fines) are often minimal.
Greene dismissed the complaint as partisan, maintaining that she “reports everything with full transparency” and that any reporting oversights were inadvertent.
Marjorie Taylor Greene Insider Trading Allegation 3: Trades Ahead of a Tariff Policy Announcement.
Most recently, Rep. Greene’s stock activity in spring 2025 ignited a fresh insider trading controversy, this time involving international trade policy. The sequence of events unfolded as follows:
Early April 2025
Greene made a series of large trades just as rumors swirled about a possible change in U.S. tariff policy. According to her official disclosures, on April 8 and 9, 2025, she purchased tens of thousands of dollars in stock across major companies.
These buys included tech and retail giants like Apple, Amazon, NVIDIA, Tesla, and others, totaling between $32,000 and $480,000 in value.
At the same time, she sold between $50,000 and $100,000 worth of U.S. Treasury bonds, moves suggesting she was repositioning her portfolio in anticipation of a market swing.
April 12, 2025
Just days after Greene’s shopping spree, former President Donald Trump made a cryptic post on his Truth Social platform declaring it was “a great time to buy” stocks.”
Mere hours later, the White House (under President Biden) announced a 90-day pause on tariffs, a significant policy shift likely to boost markets. Indeed, when the tariff pause was revealed, the stock market jumped, and many of the beaten-down stocks Greene had just bought began to rebound.
Accusations Fly
Democrats openly accused Greene of having advance knowledge of the tariff decision and profiting from insider information. They also questioned if Trump tipped off close allies to “buy the dip” before the public announcement.
The issue boiled over publicly on May 10, 2025, during a House committee hearing that Greene was chairing.
In an unusual scene, Democratic Reps. Jasmine Crockett and Greg Casar interrupted the hearing to press Greene about her April stock moves. “We’re here because [Greene] thinks she can pick on vulnerable people to avoid discussing the allegations of insider trading against her,” Rep. Casar charged, linking the stock trades to Greene’s attempt to change the subject in the hearing.
The clash grew so heated that the proceeding had to be adjourned for about 20 minutes. The message was clear: Greene’s colleagues believed her tariff-related trades smelled of insider trading, and they weren’t shy about saying so in public forums.
Greene’s Defense
Confronted with the tariff trade allegations, Greene again flatly denied any wrongdoing. She labeled the claims a “partisan smear” and insisted she had “no advance knowledge” of the tariff pause decision.
At a town hall meeting in mid-April 2025, Greene told reporters that she has “a fiduciary agreement with [her] portfolio manager” and doesn’t personally execute trades “He did a great job – guess what he did? He bought the dip,” she said, arguing that any investor could see the market was heading down and would buy accordingly.
In Greene’s view, her advisor was simply capitalizing on a market panic, not acting on insider info. She emphasized that all her trades were disclosed as required and within legal windows.
Verdict: No Charges to Date
No official entity (e.g., the House Ethics Committee or the SEC) has found Greene guilty of insider trading.
Past probes into other lawmakers’ pandemic-era trades (such as Senators Kelly Loeffler and David Perdue in 2020) ended without charges. Greene faces a similar situation with lots of suspicions and political blowback, but no legal action.
Simply making fortuitous trades is not illegal by itself; prosecutors would need proof that she traded based on material nonpublic information. That kind of evidence is hard to come by, and Greene flatly denies any wrongdoing. She has consistently maintained that her trades were made by a third-party financial advisor and that she did not profit from any secret information.
Under the STOCK Act, lawmakers must promptly disclose transactions so the public can scrutinize potential conflicts. Greene did file the required Periodic Transaction Reports for her 2022 and 2025 trades, which is how the media and watchdogs learned of them, but her compliance has not been perfect.
The 2023 ethics complaint alleges she skirted the rules by delaying or omitting certain reports in the past. Such lapses can violate federal law, although enforcement tends to be lax (often just a small fine).
The bigger consequence for Greene has been reputational. Each revelation of a suspiciously timed trade has brought a wave of negative headlines and public skepticism about whose interests she is serving.
This is not a partisan issue alone; members of both parties, including high-profile figures like former House Speaker Nancy Pelosi, have faced similar criticism for trading stocks while in office. That backdrop has spurred efforts to ban congressional stock trading entirely.
Greene’s trading activity will likely remain under the microscope as the debate over lawmakers’ stock trading rages on.